doi: 10.3389/fmed.2026.1752341 Received 23 November 2025 Revised 04 April 2026 Accepted 10 April 2026 Published 29 April 2026 Volume 13 - 2026 Edited by Wei Liu, Huazhong University of Science and Technology, China Reviewed by Jheng-Yan Wu, Chi Mei Medical Center, Taiwan Jennifer Teske, University of Arizona, United States Updates Copyright 2026 Fang, Zhu, Rao and Liu
In clinical studies, liraglutide and semaglutide both led to an average 0.3-point drop in A1c in prediabetic participants (after 56 weeks for liraglutide 5 and 68 weeks for semaglutide 6 )a small but meaningful shift for people whose blood sugar is creeping upward toward the diabetes threshold
Footnotes Conflicts of interest There are no conflicts of interest associated with this manuscript
Stay hydrated and eat in smaller portions to prevent nausea and constipation
For example, the LEADER trial showed that Liraglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 13% and cardiovascular death by 22% in comparison to placebo
